TechCrunch
SEPTEMBER 9, 2021
Neuroglee Therapeutics , a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10 million Series A led by Openspace Ventures and EDBI. million to develop digital therapeutics for neurodegenerative diseases. Neuroglee gets $2.3
TechCrunch
APRIL 6, 2022
As a venture firm that invests in psychedelics, we receive hundreds of pitches every month from founders developing psychedelic therapeutics. Our fund has invested more than $15 million in companies developing psychedelic therapeutics. Greg Kubin is a partner at PsyMed Ventures and co-host of Business Trip.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
TechCrunch
DECEMBER 20, 2021
But startups will continue to lead the way in innovation with the use of AI, IoT and data analytics, especially with data becoming the central currency of healthcare. Digital therapeutics will rewrite the future of healthcare. Healthcare deals were hot in the first nine months in 2021. They brought in a total of $21.3
TechCrunch
DECEMBER 3, 2020
Neuroglee , a Singapore-based health tech startup, wants to help with a digital therapeutic platform created to treat patients in the early stages of the disease. one of Japan’s largest pharmaceutical companies, and Kuldeep Singh Rajput, the founder and chief executive officer of predictive healthcare startup Biofourmis.
TechCrunch
MAY 12, 2023
Amongst these questions are actual costs of therapies, reimbursement coverage, the commercialisation strategy for psychedelic drug development companies, resource bottlenecks with the therapists’ supply and infrastructure, etc,” they told TechCrunch+. Drug development is very costly, and start-ups are having a harder time raising cash.
TechCrunch
NOVEMBER 3, 2021
As the world’s population ages, more is being learned about brain health as startups leverage technology to find a way to slow down cognitive impairment. This startup just raised $8 million to help busy doctors assess the cognitive health of 50 million seniors.
AsiaTechDaily
APRIL 30, 2022
Register Biofourmis , a Sigapore-founded digital therapeutics firm , announced that it has surpassed unicorn status with a $300 million Series D investment led by leading global growth equity firm General Atlantic. Bookmark ( 0 ) Please login to bookmark Username or Email Address Password Remember Me No account yet?
Expert insights. Personalized for you.
93 
Let's personalize your content